BiotechTube

DNL126

Phase 1/2Active
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mucopolysaccharidosis Type IIIA

Conditions

Mucopolysaccharidosis Type IIIA

Trial Timeline

Dec 7, 2023 → Aug 1, 2028

NCT ID
NCT06181136

About DNL126

DNL126 is a phase 1/2 stage product being developed by Denali Therapeutics for Mucopolysaccharidosis Type IIIA. The current trial status is active. This product is registered under clinical trial identifier NCT06181136. Target conditions include Mucopolysaccharidosis Type IIIA.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06181136Phase 1/2Active

Competing Products

20 competing products in Mucopolysaccharidosis Type IIIA

See all competitors
ProductCompanyStageHype Score
OdiparcilInventivaPhase 2
47
anakinraSwedish Orphan BiovitrumPhase 1/2
40
laronidaseSanofiApproved
84
LaronidaseSanofiApproved
84
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 2
51
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
84
Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)SanofiPhase 1/2
40
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
76
rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3
76
Aldurazyme + Aldurazyme + placeboSanofiPhase 3
76
LaronidaseSanofiApproved
84
JR-141JCR PharmaceuticalsPhase 2/3
64
JR-441 + JR-441 + JR-441JCR PharmaceuticalsPhase 1/2
40
JR-446JCR PharmaceuticalsPhase 1/2
40
JR-171JCR PharmaceuticalsPhase 1/2
40
JR-141JCR PharmaceuticalsPhase 2
51
JR-141 + Idursulfase + JR-141 or IdursulfaseJCR PharmaceuticalsPhase 3
76
JR-141JCR PharmaceuticalsPhase 3
76
JR-171 (lepunafusp alfa)JCR PharmaceuticalsPhase 1/2
40
JR-141JCR PharmaceuticalsPhase 1/2
40

Other Products from Denali Therapeutics

tividenofusp alfaPhase 2/3
60
DNL343 + Matching PlaceboPhase 2/3
60
tividenofusp alfa + idursulfasePhase 2/3
60
DNL593 + PlaceboPhase 1/2
36
tividenofusp alfaPhase 1/2
36